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Case presentation
A 65 years-old Italian woman came to our attention at the Me-
dicina-Malattie Metaboliche dell’Osso Department. She came
as an outpatient and the reason of the visit was persistent bone
pain. 
Through family history of the patient, it was possible to ascer-
tain a familial form of Paget’s disease of bone (PDB), because
the father, two uncles and 4 cousins (2 males and 2 females)
were affected by the disease, suggesting that the disease seg-
regates in an autosomal dominant pattern (Figure 1). She was
diagnosed with Paget’s disease of bone when she was 62
years-old because of the occasional finding of an elevated al-
kaline phosphatase and subsequent bone scintigraphy. Bone
scintigraphy showed signs of disease at right pelvis, right proxi-
mal femur and IV and VIII left ribs. 
After the diagnosis of PDB she was followed-up at our Depart-
ment with clinical evaluation and dosage of alkaline phos-
phatase every 4 months, and she was treated with clodronate
infusion whenever bone pain was reported or alkaline phos-
phatase level was more than twice the laboratory upper limit.
During the period from the diagnosis of Paget’s disease when
she was 62 years old until the age of 65, a total of 3 clodronate
infusion (each consisting in five days courses with clodronate
300 mg daily) were employed, without significant side effects
and with a good response in term of clinical and biochemical
parameters.
Three years after the diagnosis of PDB, bone pain at right
pelvis markedly increased.
On physical examination she had normal motility of her hips,
and tenderness of the right inguinal region was observed.
Alkaline phosphatase was 2259 U/L (upper normal limit 145
U/L), with serum calcium levels into the normal range. 
In the hypothesis of a reactivation of pagetic symptoms, a new
clodronate infusion (consisting in five infusions with clodronate
300 mg daily) was employed.
After one month the patient described persistent and increased
bone pain at the right hip.
A new dosage of bone turnover markers was done along with
blood count and basic chemistry: alkaline phosphatase level
was 2160 U/L, markers of inflammation were elevated and mild
anemia was found. 
An x-ray evaluation of the right hip was performed, showing an
ill-defined destructive radiolucent lesion in the neck of the fe-
mur, with multifocal cortical disruption.
Therefore, the patient was admitted to the Hospital and a bone
biopsy was performed at the right hip on the site of involvement.
The histologic examination of the biopsy showed “osteoid matrix
in which there is a proliferation of spindle cells with atypia, with
irregular nuclei. Cells with the same characteristics diffusely infil-
trate the muscle present in the specimen”. It was diagnostic of
an osteogenic sarcoma with muscle fibers involvement. 
A chest X-ray was also performed: it showed bilateral pul-
monary nodules, subsequently confirmed as secondary dis-
semination by CT.
To further stage the osteosarcoma, an MRI of the hip was per-
formed, confirming the involvement of the right femoral neck. 
According with the Oncologist consultant, the lesion was con-
sidered not treatable with surgery because of the metastatic le-
sions, and it was decided to start a treatment with ifosfamide (3
g/m2 in 48 hours), adriamicine (60 mg/m2 for 24 hours) and cis-
platinum (100 mg/m2 for 48 hours) with a palliative intent.
Pamidronate 90 mg e.v. was also administered in order to re-
duce local pain.
In the subsequent days, a partial reduction of local pain was
observed.
Unfortunately, patient died 3 months after the diagnosis of os-
teosarcoma.
Discussion
Familial Paget’s disease accounts for about 20% of PDB cases,
and it is often found to segregate in an autosomal dominant pat-
tern. Mutations of p62/sequestosome 1 gene (S Q ST M 1 / p 6 2) ac-
count for familial forms of PDB (1). 
It is well known that the presentation of familial PDB is most
frequently poliostotic than in sporadic cases, and that levels of
alkaline phosphatase are frequently higher.
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Figure 1- Genealogic tree of the patient discussed. Patient case corre-
sponds to subject III-6. With kind permission of Alberto Falchetti, M.D.
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From PDB diagnosis, patient was treated with antireabsorptive
therapy. There are four general indications for treatment of
Paget’s disease: symptoms due to metabolically active Paget’s
disease such as bone pain or neurological syndromes; patient
planning to undergo elective surgery on a pagetic site; the
management of hypercalcemia, a rare occurrence following
prolonged immobilization; finally, some investigators believe
that treatment is indicated as an attempt to decrease local pro-
gression and reduce the risk of future complications. 
Nowadays pharmacological treatment is based upon the use of
bisphosphonates. 
Bisphosphonates approved by the US Food and Drug Adminis-
tration for the treatment of Paget’s disease include
pamidronate, which is given intravenously, and etidronate, tilu-
dronate, alendronate and risedronate, all of which are taken
orally. Clodronate, though not approved for treatment of
Paget’s disease in many countries, has been successfully
used. Daily infusions of clodronate 300 mg for 5 days have
showed the ability to significantly reduce disease activity (2, 3). 
Our patient was repeatedly treated with clodronate infusions
with a satisfying clinical and biochemical response during the
past years.
Investigators have recognized that secondary resistance to in-
dividual bisphosphonates can occur. Therefore, it may be nec-
essary for a patient to use more than one bisphosphonate in
long-term management of the disease (4). 
In this patient, after the diagnosis of osteosarcoma was made,
we used pamidronate to obtain both an antiresorptive effect
and a reduction of pain. 
It is important to search and diagnose all familial cases of
Paget’s disease of bone in order to treat them and to avoid the
occurrence of future severe complications in these subjects.
In fact, a number of complications may result from Paget’s dis-
ease. Of these, the most devastating is a transformation of the
bone that becomes cancerous. Osteosarcoma or other types of
sarcoma occurs in less than 1 percent of patients with Paget’s
disease, with a significantly higher rate than in non-PDB indi-
viduals. Malignant complication is mostly described over 70
years of age, after a large number of years from PDB diagno-
sis, and it is often rapidly progressive with early metastasis and
death.
Osteosarcoma is the most common type of Paget’s sarcoma.
Skeletal distribution of these tumors mirrors that of Paget’s dis-
ease. A patient presents with the sudden onset of a mass
and/or severe pain at the site of previously-asymptomatic
Paget’s disease. Frequently, this presents as a pathologic frac-
ture. Pain is the most reliable indicator of malignant transfor-
mation in Paget’s disease.
In the case of our patient, the symptom of presentation was
bone pain, at first misdiagnosed as a possible reactivation of
the pagetic lesion, but subsequently suspected as a malignant
evolution. 
On radiograph, there is development of a radiolucent, destruc-
tive process within a well-established area of pagetic bone.
The early, destructive phase of Paget’s can be confusing. Mul-
tiple, small radiolucencies are less suggestive than a single,
large area. The lucencies must be clearly destructive and pro-
gressive to reliably indicate malignant transformation.
On isotope scan, it is often difficult to distinguish between the
increased uptake in the lesion and that seen in Paget’s dis-
ease. This study is not helpful unless there is a dramatic
change.
Preoperative evaluation of the extent of local disease was per-
formed with MRI (5).
Diagnosis is based and confirmed on biopsy (Figure 2).
Microscopic features are strikingly varied within a single le-
sion. Areas of high-grade, classic osteosarcoma can usually
be found but are often overshadowed by other areas of undif-
ferentiated spindle cells, fibrosarcoma, malignant fibrous his-
tiocytoma, chondrosarcoma, and even giant cell tumor. For
this reason, some prefer to call the lesion "Paget’s sarcoma"
rather than osteosarcoma. The lesional cells often infiltrate
the adjacent, Pagetic bone, and plugs of tumor are frequently
seen within the large, vascular channels peculiar to Pagetic
b o n e .
After the diagnosis of sarcoma has been made, a thorough
search for evidence of intrathoracic disease should be per-
formed because pulmonary nodules are the most common site
of metastatic disease for both soft tissue and bone sarcomas. If
chest radiographic findings are normal, chest computed tomog-
raphy should be performed. The discovery of metastatic dis-
ease clearly influences decisions about the need to subject the
patient to aggressive local therapy to achieve long-term local
control.
Surgical treatment, when possible, is indicated. Radical mar-
gins, usually amputation, are required for reliable, local control.
The prognosis, even with local control, is dismal.
In our patient the site of the lesion would have required a de-
structive operation, furthermore, the presence of pulmonary
metastasis contraindicated surgical excision.
Chemotherapy is currently used, but when dealing with os-
teosarcoma in Paget’s disease, response to chemotherapy is
generally much less positive than with classic osteosarcoma. It
seldom provides meaningful alteration in the rapid, downhill
course and is often devastating to the remaining lifestyle in this
age group. Two randomized clinical studies have documented
significant benefit using adjuvant chemotherapy in patients pre-
senting with osteogenic sarcoma (6,7). 
In conclusion, at the moment prognosis of bone sarcoma in
PDB remains generally poor due to late and difficult diagnosis,
high grade of malignancy of the tumors, difficulties at their sur-
gical removal and the old age of patients. 
The particularity of the case presented above was the early oc-
currence of bone sarcoma in a case of polyostotic Paget’s dis-
ease with a family history segregating in an autosomal domi-
nant pattern.
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Figure 2 - Histologic features of bone biopsy: osteoid matrix in which
there is a proliferation of spindle cells with atypia, with irregular nuclei. 
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